Annual report [Section 13 and 15(d), not S-K Item 405]

Commitments and Contingencies - Additional Information (Details)

v3.26.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Aug. 08, 2025
Jul. 01, 2025
Mar. 31, 2026
Dec. 31, 2025
Dec. 31, 2024
Loss Contingencies [Line Items]          
Amount held as a retainer       $ 95,121 $ 0
Right-of-use asset       0 101,437
Operating Lease Expenses       118,277 141,182
Short term lease payments       $ 19,958 $ 21,959
Lessor, Operating Lease, Description       The Office Lease contained escalating payments during the lease period. Upon execution of the Office Lease, the Company prepaid one month of rent, which applied to the first month's rent, and a security deposit, which is held in escrow and will be credited after the termination of the lease with a refund expected in the first half of 2026.  
Prepaid Expenses And Other Current Assets Member          
Loss Contingencies [Line Items]          
Lease Security Deposit       $ 25,000  
Clinical Trial Supply Organization [Member]          
Loss Contingencies [Line Items]          
Amount of clinical trial supply   $ 6,500,000      
Estimated total remaining contract costs       6,300,000  
Contract Research Organization [Member]          
Loss Contingencies [Line Items]          
Estimated total remaining contract costs       18,400,000  
Contigent payment of performance milestones       2,600,000  
Performance milestones $ 2,600,000        
Clinical Research Study $ 25,500,000        
Amount held as a retainer       1,000,000  
Passthrough Costs       900,000  
Contract Research Organization [Member] | Prepaid Expenses And Other Current Assets Member          
Loss Contingencies [Line Items]          
Upfront Payment       $ 1,900,000  
Contract Research Organization [Member] | Forecast [Member]          
Loss Contingencies [Line Items]          
Contigent payment of performance milestones     $ 7,500,000    
Total potential milestone payments     48,200,000    
Increasing the total contracted amount     73,700,000    
Lexington [Member]          
Loss Contingencies [Line Items]          
Incremental Borrowing Rate       12.00%  
Operating lease liabilities       $ 0  
Sphaera Pharma Pte. Ltd. [Member]          
Loss Contingencies [Line Items]          
Total potential milestone payments       500,000  
Net sales of FDA approved drug       $ 4,400,000  
Subsequent Event [Member]          
Loss Contingencies [Line Items]          
Contigent payment of performance milestones     7,500,000    
Total potential milestone payments     48,200,000    
Increasing the total contracted amount     $ 73,700,000